TO LISTEN TO THE PODCAST CLICK THE PLAY BUTTON BELOW
The content of this podcast / blog (or content associated with it) is not intended as investment advice and people featured may hold positions in the companies they talk about. Please do your own research.
ON TODAY’S PODCAST:
Mark Cuban, Motif Bio #MTFB Collagen Solutions #COS and Xpediator #XPD
To celebrate the 1000th episode of the Vox Markets Podcast I’m joined by renowned US billionaire, Shark Tank investor & Dallas Mavericks owner Mark Cuban.
Mark speaks about how he made his billions, his investment strategies, cryptocurrency, Brexit and Trump.
(Interview starts at 1 minute 57 seconds)
Graham Lumsden, CEO Motif Bio #MTFB speaks about the three iclaprim abstracts that have been accepted for presentation at the upcoming 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID 2018) to be held in Madrid on April 21-24.
Motif Bio plc (AIM/NASDAQ: MTFB) is a clinical-stage biopharmaceutical company engaged in the research and development of novel antibiotics designed to be effective against serious and life-threatening infections in hospitalised patients caused by multi-drug resistant bacteria, including MRSA. The Company’s lead product candidate, iclaprim, is being developed for high-risk MRSA patient populations. The first proposed indication, and near-term commercial opportunity, is for the treatment of ABSSSI, one of the most common bacterial infections, with 3.6 million patients hospitalised annually in the U.S. The Company believes that iclaprim may be suitable for first-line empiric therapy in ABSSSI patients, especially those with renal impairment, with or without diabetes. Unlike current standard of care antibiotics, in clinical trials to date, nephrotoxicity has not been observed with iclaprim and dosage adjustment has not been required in patients with renal impairment.
(Interview starts at 27 minutes 37 seconds)
Collagen Solutions Plc is a global supplier, developer, and manufacturer of medical grade collagen, tissues, and related medical devices and components for use in regenerative medicine, medical devices and in-vitro diagnostics and research. The Company is also expanding its range of biomaterials-based finished medical devices based on its internal and acquired intellectual property for commercialisation with partners via licensing and distribution arrangements, including ChondroMimetic®. The Company’s products are used in a wide variety of applications including orthopaedics, cardiovascular, dental, plastic surgery, wound healing, neurology and urology.
(Interview starts at 35 minutes 50 seconds)
Xpediator is a well-established international provider of freight management services. Established in 1988 by CEO Stephen Blyth today the Company’s international network of offices provides regular and direct services linking Eastern Europe, the Balkans and the Baltics with Western Europe, together with logistics and warehousing in the UK and Romania. The business offers integrated freight management within the supply chain logistics and fulfilment sector, through their three main areas: freight forwarding, logistics & warehousing and transport services. With headquarters in Braintree, Essex and country offices in eight CEE countries across 22 sites, the Group currently employs over 690 people and was successfully listed on London’s AIM market in August 2017.
(Interview starts at 46 minutes 19 seconds)
(Feature starts at 53 minutes 43 seconds)
1. Download the Vox Markets app by clicking here (for either iPhone or Android).
2. Search for a company you want to receive the RNS’s from.
3. Click, “Follow” on that company’s page.
The content of this podcast (or content associated with it) is not intended as investment advice and people featured may hold positions in the companies they talk about. Please do your own research.